Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ptk787 + verteporfin
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**PTK787 + verteporfin** is an experimental combination therapy consisting of PTK787 (vatalanib), an oral inhibitor of vascular endothelial growth factor receptors (VEGFRs), and verteporfin, a photosensitizer used in photodynamic therapy (PDT) primarily for choroidal neovascularization secondary to conditions like age-related macular degeneration (AMD). PTK787 acts as an anti-angiogenic agent by inhibiting VEGFR-mediated signaling, aiming to reduce abnormal blood vessel growth and leakage. Verteporfin, when activated by light, generates reactive oxygen species to selectively destroy abnormal neovascular tissue. The rationale for their combination is to enhance anti-neovascular effects: verteporfin targets the destruction of existing pathological vessels, while PTK787 aims to suppress subsequent neovascularization driven by VEGF upregulation post-PDT[1][4].
- Other names
- zd6474zd-6474zd 6474vatalanib
02
Targets
PDGFR (PDGFR family)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TEAD (TEAD family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on ptk787 + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ptk787 + verteporfin.